• 提示：详情请下载说明书。

• 产品描述： Crizotinib (PF-02341066) hydrochloride (Xalkori) 可抑制 c-Met 和核磷脂(NPM)-anaplastic lymphoma kinase (ALK) 的酪氨酸磷酸化，对应基于细胞的测定中的IC5​​0值分别为 11 nM 和 24 nM。Crizotinib hydrochloride 也是一种有效的 ROS1 的抑制剂，Ki值小于0.025 nM。Crizotinib 可通过抑制多种肺癌细胞系中的STAT3途径诱导自噬

• 靶点： ROS1(Cell-free assay):<0.025 nM(Ki); c-Met(Cell-based assay):11 nM;NPM-ALK(Cell-based assay):24 nM;c-Met/HGFR;ROS;ALK;Autophagy;ROSKinase

• 体内研究：
  In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displa

• 细胞实验： Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells Concentrations: 0-256 nM Incubation Time: 1 h Method: Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of p

• 动物实验： Animal Models: Female or male nu/nu mice bearing NCI-H441,or DLD-1, or MDA-MB-231 Dosages: 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day Administration: p.o.

• 参考文献：
  1. Helen Y Zou, et al. Cancer Res. 2007 May 1;67(9):4408-17. 2. Helen Y Zou, et al. Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3493-8. 3. Liangkun You, et al. Oncotarget. 2015 Nov 24;6(37):40268-82. 4. Zou HY, et al. Cancer Res. 2007, 67(9), 4408-4417.

• 溶解性： Soluble  in  DMSO、Ethanol、H2O

• 保存条件： -20°C;充氩

• 配置溶液浓度参考：
  

  	1mg	5mg	10mg
  1 mM	2.054 ml	10.271 ml	20.542 ml
  5 mM	0.411 ml	2.054 ml	4.108 ml
  10 mM	0.205 ml	1.027 ml	2.054 ml
  50 mM	0.041 ml	0.205 ml	0.411 ml

• 注意：部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。

输入产品批号：

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *